Abstract library

525 results for "progression".
#654 Identification of Signaling Pathways Involved in Lung Carcinoid Progression Using Gene Expression Profiling
Introduction: Lung carcinoids are well-differentiated neuroendocrine tumors (NETs) usually associated with a favorable prognosis. Mechanisms underlying progression are poorly understood.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MSc Dorian Swarts
#862 The Role of Chromogranin A as a Predictor of Radiological Disease Progression in Midgut and Pancreatic Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is an established neuroendocrine biomarker. However, its role as a predictor of radiological disease progression in all neuroendocrine tumors (NETs) has not been recognised yet.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Roberta E Rossi
#866 Plasma Chromogranin B as a Marker of Tumor Burden and Radiological Progression in Neuroendocrine Tumors
Introduction: Chromogranin-B (CgB) is expressed in most neuroendocrine tumors (NETs), yet little is understood about its clinical utility as a biomarker.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: David Braude
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...
#603 Role of Semaphorins and Their Signaling Pathway in the Progression of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Semaphorin family, a part of axon guidance molecules, is involved in many types of epithelial cancers. However, little is known about its potential function in GEP-NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Colette Roche
#997 Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET)
Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Florian Keplinger
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto
#1707 Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?
Introduction: Small intestinal neuroendocrine tumors (siNETs) are rare tumors that raise several clinical and therapeutic challenges. Current treatments are not efficient, in part because of a poor understanding of their mechanisms of progression. We recently highlighted some axon guidance molecules (AGMs) that might be implicated in the progression of siNETs. Among them, we are currently focusing our efforts on the semaphorin 3F receptor neuropilin-2 (NRP2).
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D Julien Bollard
Keywords: siNETs, progression, NRP2
#1394 The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression
Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Lyle M, Wyld D, Burge M, ...